Payment overview · 2025
General Payments
$1,180.31
79 reported records · 18 companies
Healthcare provider profile · identity verified
Chad Allen Prior, MD
Allopathic & Osteopathic Physicians|Internal Medicine · GREEN VALLEY, AZ · NPI 1790772036
Verified facts
What the public records show
CMS Open Payments records show Chad Allen Prior, MD received $1,180.31 in general payments during 2025 across 79 reported records.
Amgen Inc. accounted for 17.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Mounjaro, Ozempic, Prolia, Rybelsus, Trelegy Ellipta, Tymlos.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Paxlovid by this doctor in 2024.
Radius Health, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tymlos as an associated drug or biological on 17199 records involving 7328 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Tymlos by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $204.26 | 17.3% | 23 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $186.27 | 15.8% | 16 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $157.45 | 13.3% | 8 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $84.58 | 7.2% | 5 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $71.31 | 6.0% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $67.56 | 5.7% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $62.30 | 5.3% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $57.00 | 4.8% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $49.32 | 4.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $44.62 | 3.8% | 3 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $42.08 | 3.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $36.52 | 3.1% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $27.99 | 2.4% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $19.62 | 1.7% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $19.61 | 1.7% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $19.07 | 1.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.99 | 1.4% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.76 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,180.31 | 79 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $186.27 | 16 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $105.00 | 10 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $99.26 | 13 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $90.62 | 4 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $80.00 | 8 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $75.26 | 10 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $71.31 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $69.86 | 4 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $67.56 | 3 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $67.56 | 3 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $62.30 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $59.45 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $57.00 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $57.00 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $49.32 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $42.08 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $36.52 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $30.56 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $30.56 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $27.99 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $19.62 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $19.61 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.99 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.99 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.99 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.72 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.06 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $13.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 45 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 42 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 69 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 21 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 114 | exact normalized | Medicare Part D |
| Tymlos tymlos |
2025 | Tymlos | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
72 | 27 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
21 | 14 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
32 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
54 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
114 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
85 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
42 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
69 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
163 | 56 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
23 | 23 |
| Radius Health, Inc. Exact reporting entity; no affiliate inference |
2025 | Tymlos open payments reported associated product |
CMS Open Payments — General Payments 17199 supporting records · 7328 recipient NPIs · example record 1249501587 |
Tymlos · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
45 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 967 | 327 |
| Levothyroxine Sodium | Levothyroxine Sodium | 852 | 272 |
| Losartan Potassium | Losartan Potassium | 848 | 268 |
| Amlodipine Besylate | Amlodipine Besylate | 654 | 228 |
| Lisinopril | Lisinopril | 557 | 189 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 497 | 177 |
| Gabapentin | Gabapentin | 366 | 142 |
| Simvastatin | Simvastatin | 366 | 119 |
| Tamsulosin Hcl | Tamsulosin Hcl | 363 | 133 |
| Omeprazole | Omeprazole | 344 | 119 |
| Metformin Hcl | Metformin Hcl | 321 | 112 |
| Hydrochlorothiazide | Hydrochlorothiazide | 315 | 111 |
| Pantoprazole Sodium | Pantoprazole Sodium | 308 | 124 |
| Pravastatin Sodium | Pravastatin Sodium | 308 | 100 |
| Allopurinol | Allopurinol | 284 | 90 |
| Metoprolol Succinate | Metoprolol Succinate | 274 | 93 |
| Furosemide | Furosemide | 244 | 90 |
| Metoprolol Tartrate | Metoprolol Tartrate | 219 | 78 |
| Finasteride | Finasteride | 206 | 74 |
| Montelukast Sodium | Montelukast Sodium | 186 | 64 |
| Alendronate Sodium | Alendronate Sodium | 184 | 74 |
| Eliquis | Apixaban | 163 | 56 |
| Sertraline Hcl | Sertraline Hcl | 163 | 60 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 158 | 74 |
| Potassium Chloride | Potassium Chloride | 151 | 47 |
| Trazodone Hcl | Trazodone Hcl | 151 | 55 |
| Famotidine | Famotidine | 144 | 53 |
| Carvedilol | Carvedilol | 139 | 48 |
| Ezetimibe | Ezetimibe | 138 | 54 |
| Lovastatin | Lovastatin | 121 | 36 |
| Citalopram Hbr | Citalopram Hydrobromide | 117 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 115 | 39 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 114 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 104 | 35 |
| Metformin Hcl Er | Metformin Hcl | 102 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 101 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 99 | 39 |
| Fluoxetine Hcl | Fluoxetine Hcl | 94 | 31 |
| Donepezil Hcl | Donepezil Hcl | 93 | 31 |
| Meloxicam | Meloxicam | 89 | 34 |
| Jardiance | Empagliflozin | 85 | 25 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 85 | 20 |
| Atenolol | Atenolol | 83 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 83 | 43 |
| Glipizide | Glipizide | 79 | 27 |
| Glipizide Er | Glipizide | 79 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 77 | 22 |
| Tramadol Hcl | Tramadol Hcl | 76 | 30 |
| Xarelto | Rivaroxaban | 76 | 23 |
| Bupropion Xl | Bupropion Hcl | 74 | 23 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 74 | 22 |
| Glimepiride | Glimepiride | 72 | 24 |
| Synthroid | Levothyroxine Sodium | 72 | 27 |
| Spironolactone | Spironolactone | 70 | 23 |
| Estradiol | Estradiol | 69 | 29 |
| Ozempic | Semaglutide | 69 | 20 |
| Warfarin Sodium | Warfarin Sodium | 65 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 61 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 60 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 57 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 55 | 21 |
| Repatha Sureclick | Evolocumab | 55 | 13 |
| Celecoxib | Celecoxib | 54 | 26 |
| Farxiga | Dapagliflozin Propanediol | 54 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 54 | 16 |
| Cephalexin | Cephalexin | 49 | 43 |
| Propranolol Hcl | Propranolol Hcl | 48 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 46 | 17 |
| Gemtesa | Vibegron | 45 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 44 | 12 |
| Solifenacin Succinate | Solifenacin Succinate | 44 | 17 |
| Ipratropium Bromide | Ipratropium Bromide | 43 | 20 |
| Benazepril Hcl | Benazepril Hcl | 42 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 42 |
| Mounjaro | Tirzepatide | 42 | 13 |
| Pregabalin | Pregabalin | 42 | 21 |
| Valacyclovir | Valacyclovir Hcl | 42 | 25 |
| Methylprednisolone | Methylprednisolone | 41 | 39 |
| Paroxetine Hcl | Paroxetine Hcl | 41 | 14 |
| Prednisone | Prednisone | 41 | 28 |
| Azelastine Hcl | Azelastine Hcl | 40 | 23 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 39 | suppressed |
| Clonazepam | Clonazepam | 39 | 13 |
| Memantine Hcl | Memantine Hcl | 39 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 39 | suppressed |
| Baclofen | Baclofen | 38 | 21 |
| Liothyronine Sodium | Liothyronine Sodium | 37 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 37 | suppressed |
| Lorazepam | Lorazepam | 36 | 24 |
| Sumatriptan Succinate | Sumatriptan Succinate | 36 | 12 |
| Enalapril Maleate | Enalapril Maleate | 35 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 35 | 22 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 29 |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 32 | 11 |
| Myrbetriq | Mirabegron | 32 | 14 |
| Ramipril | Ramipril | 32 | suppressed |
| Temazepam | Temazepam | 32 | 12 |
| Acyclovir | Acyclovir | 31 | 16 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 31 | 11 |
| Valsartan | Valsartan | 31 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 30 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Alprazolam | Alprazolam | 29 | 16 |
| Clonidine Hcl | Clonidine Hcl | 29 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 29 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Dutasteride | Dutasteride | 28 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | 11 |
| Rybelsus | Semaglutide | 28 | suppressed |
| Naproxen | Naproxen | 27 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 26 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 26 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 19 |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Nystatin | Nystatin | 23 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 23 |
| Propranolol Hcl Er | Propranolol Hcl | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 21 |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Prolia | Denosumab | 21 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 20 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 17 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Colchicine | Colchicine | 17 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 12 |
| Primidone | Primidone | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Loperamide | Loperamide Hcl | 16 | suppressed |
| Minoxidil | Minoxidil | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 15 | suppressed |
| Armour Thyroid | Thyroid,pork | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 12 |
| Linzess | Linaclotide | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 13 |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Tymlos | Abaloparatide | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 12 |
| Azithromycin | Azithromycin | 12 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Mesalamine | Mesalamine | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Budesonide Dr | Budesonide | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,180.31 · 79 records | Amgen Inc. | ABRYSVO, AIRSUPRA, BREZTRI, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, EVENITY, GARDASIL 9, GEMTESA, INSPIRE, LEQVIO, MOUNJARO, OTEZLA, Ozempic, PREVNAR 20, PROLIA, REPATHA, Rybelsus, SHINGRIX, Senza, TRELEGY ELLIPTA, Tymlos, VRAYLAR, Veozah, WATCHMAN FLX, Wegovy, YUPELRI, ZENPEP, ZEPBOUND | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error